Form 4: Precigen Inc. Executive Acquires 300,000 Stock Options

Jeffrey Thomas Perez, SVP of IP Affairs at Precigen, Inc., acquired 300,000 stock options on May 31, 2024.

Summary

• On May 31, 2024, Jeffrey Thomas Perez, SVP of IP Affairs at Precigen, Inc., acquired 300,000 stock options.
• The options have an exercise price of $1.40.
• The options vest 25% on May 31, 2025, and the remaining 75% vest in equal monthly installments over the following three years.
• The options expire on May 31, 2034.
• Following the transaction, Perez directly owns 300,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is required when a company insider (officer, director, or 10% owner) buys or sells shares of the company's stock. It provides transparency into insider transactions.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule of 25% after one year followed by monthly vesting over three years is a typical arrangement.
• Comparing the size of the grant to those of executives at comparable companies (e.g., Intellia Therapeutics, CRISPR Therapeutics) would provide further context.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• Shareholders may view the option grant as a sign of confidence from the executive.

Key Dates